Back to search results

Personalized Cancer Support (Thrive Track) for Young Adults with Thyroid, Melanoma, or Testicular Cancer

This study is testing a website called Thrive Track, which aims to help young adults (ages 20-39) with thyroid, melanoma, or testicular cancer manage their emotional needs. Some participants will receive access to the Thrive Track website with general cancer information, while others will also get emotional support content. The researchers want to see if adding emotional support helps reduce cancer-related worry and distress after three months. This study is for young adults diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer. The goal is to understand how different levels of online support can improve coping and quality of life for young adult cancer survivors.

Study design
This study plans to enroll 142 participants and compares two different versions of an internet-based intervention.
What's involved
Participants will access the Thrive Track website and complete questionnaires and interviews.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 3 months after joining the study to measure cancer-related worry and distress.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07529080

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

Not Yet Recruiting
NAAges 20–39InterventionalSupportive care
University of Michigan Rogel Cancer Center
~142 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Internet-Based InterventionInterviewQuestionnaire Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cancer related worry
Measured over 3 months post-enrollment
+1 more outcome measured

Conditions

Differentiated Thyroid Gland Carcinoma
Malignant Testicular Neoplasm
Melanoma
Thyroid Gland Follicular Carcinoma
Thyroid Gland Papillary Carcinoma

Explore related trials

Malignant Testicular NeoplasmMelanomaThyroid Gland Follicular CarcinomaThyroid Gland Papillary Carcinoma

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Megan R Haymart, MD · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

Megan Haymart, MD
[email protected]
734-615-6745
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PARTICIPANTS RECRUITED FROM SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM (SEER)-GEORGIA: Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer at any stage and reported to the SEER-Georgia registry
PARTICIPANTS RECRUITED FROM SEER-GEORGIA: 2-10 years after diagnosis with cancer
PARTICIPANTS RECRUITED FROM SEER-GEORGIA: English speaking (able to read and speak English)
PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Residing in the United States
PARTICIPANTS RECRUITED FROM THYROID CANCER SURVIVORS' ASSOCIATION INC. (THYCA): Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
PARTICIPANTS RECRUITED FROM THYCA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer) at any stage
PARTICIPANTS RECRUITED FROM THYCA: 2-10 years after diagnosis with cancer
PARTICIPANTS RECRUITED FROM THYCA: English speaking (able to read and speak English)
PARTICIPANTS RECRUITED FROM THYCA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
PARTICIPANTS RECRUITED FROM THYCA: Residing in the United States
PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman

Exclusion

PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman

What this trial measures

  • Cancer related worry3 months post-enrollment

    Cancer-related worry will be evaluated using two 8-item validated scales: 1. Cancer Worry Scale (CWS) 2. An adapted cancer worry scale Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the two scales between intervention and control subjects at 3 months post intervention. Scores on the CWS scale range from 8 (minimum) to 32 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes. Scores on the adapted cancer worry scale range from 8 (minimum) to 40 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.

  • Cancer related distress3 months post-enrollment

    Cancer-related distress will be measured using the National Comprehensive Cancer Network Distress Thermometer. Scores on the NCCN Distress Thermometer range from 0 (minimum) to 10 (maximum), with lower scores indicating less distress and more favorable outcomes. Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the distress thermometer between the intervention and control subjects at 3 months post-intervention using two-sample t-tests.